We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

126 hedge funds and large institutions have $196M invested in ImmunityBio in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 50 increasing their positions, 26 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 26

56% more capital invested

Capital invested by funds: $125M → $196M (+$70.6M)

1.55% more ownership

Funds ownership: 8.32% → 9.87% (+1.6%)

4% less funds holding

Funds holding: 131 → 126 (-5)

19% less call options, than puts

Call options by funds: $3.06M | Put options by funds: $3.79M

22% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 23

Holders
126
Holders Change
-5
Holders Change %
-3.82%
% of All Funds
2.17%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
18
Increased
50
Reduced
26
Closed
23
Calls
$3.06M
Puts
$3.79M
Net Calls
-$722K
Net Calls Change
-$627K

Top Buyers

1
State Street
State Street
Massachusetts
+$21.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$2.54M
3
JP Morgan Chase
JP Morgan Chase
New York
+$1.83M
4
Citigroup
Citigroup
New York
+$1.64M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.59M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$3.56M
2
Morgan Stanley
Morgan Stanley
New York
-$1.53M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.49M
4
Citadel Advisors
Citadel Advisors
Florida
-$1.05M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$505K
Name Holding Trade Value Shares
Change 		Change in
Stake
S
101
SignatureFD
Georgia
$19K – – –
CUAMC
102
China Universal Asset Management Company
China
$19K +$17.1K +3,749 New
ZIG
103
Zullo Investment Group
Pennsylvania
$10K – – –
National Bank of Canada
104
National Bank of Canada
Quebec, Canada
$9K – – –
WAM
105
Worth Asset Management
Texas
$8K -$456 -100 -6%
Daiwa Securities Group
106
Daiwa Securities Group
Japan
$7K -$110K -24,106 -94%
Rockefeller Capital Management
107
Rockefeller Capital Management
New York
$7K – – –
WOC
108
West Oak Capital
California
$7K – – –
IFAM
109
Institutional & Family Asset Management
Colorado
$6K +$5.92K +1,300 New
Northwestern Mutual Wealth Management
110
Northwestern Mutual Wealth Management
Wisconsin
$5K -$273 -60 -6%
AF
111
Advisornet Financial
Minnesota
$4K – – –
AAP
112
Arax Advisory Partners
Colorado
$3K – – –
SWM
113
Spire Wealth Management
Virginia
$2K -$889 -195 -32%
PA
114
PSI Advisors
Florida
$2K – – –
US Bancorp
115
US Bancorp
Minnesota
$2K – – –
ATC
116
Adirondack Trust Company
New York
$2K +$684 +150 +50%
BWM
117
BerganKDV Wealth Management
Minnesota
$1K – – –
HNWAG
118
High Net Worth Advisory Group
Florida
$1K – – –
CCM
119
Covington Capital Management
California
$1K +$1.14K +250 New
PA
120
Parallel Advisors
California
$1K +$1.25K +275 New
Bank of Montreal
121
Bank of Montreal
Ontario, Canada
$517 +$445K +97,760 New
Renaissance Technologies
122
Renaissance Technologies
New York
– -$1.49M -401,681 Closed
Qube Research & Technologies (QRT)
123
Qube Research & Technologies (QRT)
United Kingdom
– -$505K -135,655 Closed
E
124
Ergoteles
New York
– -$503K -135,300 Closed
Tudor Investment Corp
125
Tudor Investment Corp
Connecticut
– -$354K -95,140 Closed
2 3 4
5
6

IBRX Hedge Fund Activity: Q3 2022 in Review

126 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2022, worth a combined $196M — up 56% from $125M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of IBRX and 18 opened new positions — a net loss of 5 holders — while 26 trimmed existing stakes and 50 added.

The largest buyer was State Street, adding an estimated $21.8M. The largest seller was Millennium Management, cutting an estimated $3.56M.

  • 126 institutional investors held ImmunityBio (IBRX) as of Q3 2022, down from 131 in Q2 2022.
  • Funds reported $196M of ImmunityBio stock for Q3 2022, up 56% quarter-over-quarter.
  • 18 funds opened new ImmunityBio positions in Q3 2022 and 23 closed out, a net change of -5 holders.
  • The largest ImmunityBio buyer in Q3 2022 was State Street, an estimated $21.8M added.
  • The largest ImmunityBio seller in Q3 2022 was Millennium Management, an estimated $3.56M sold.

Based on aggregated 13F filings for Q3 2022.